BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 19394838)

  • 21. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
    Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
    Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic success of boron neutron capture therapy (BNCT) mediated by a chemically non-selective boron agent in an experimental model of oral cancer: a new paradigm in BNCT radiobiology.
    Trivillin VA; Heber EM; Nigg DW; Itoiz ME; Calzetta O; Blaumann H; Longhino J; Schwint AE
    Radiat Res; 2006 Aug; 166(2):387-96. PubMed ID: 16881740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo 19F MR imaging and spectroscopy for the BNCT optimization.
    Porcari P; Capuani S; D'Amore E; Lecce M; La Bella A; Fasano F; Migneco LM; Campanella R; Maraviglia B; Pastore FS
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S365-8. PubMed ID: 19375924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo evaluation of phosphorous-containing derivatives of dodecahydro-closo-dodecaborate for boron neutron capture therapy of gliomas and sarcomas.
    Tjarks W; Barth RF; Rotaru JH; Adams DM; Yang W; Kultyshev RG; Forrester J; Barnum BA; Soloway AH; Shore SG
    Anticancer Res; 2001; 21(2A):841-6. PubMed ID: 11396173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of the tumor-suppressive effect of boron neutron capture therapy for amelanotic melanoma by intratumoral injection of the tyrosinase gene.
    Morita N; Hiratsuka J; Kondoh H; Uno M; Asano T; Niki Y; Sakurai Y; Ono K; Harada T; Imajo Y
    Cancer Res; 2006 Apr; 66(7):3747-53. PubMed ID: 16585201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential of using boric acid as a boron drug for boron neutron capture therapy for osteosarcoma.
    Hsu CF; Lin SY; Peir JJ; Liao JW; Lin YC; Chou FI
    Appl Radiat Isot; 2011 Dec; 69(12):1782-5. PubMed ID: 21420871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
    Masunaga S; Sakurai Y; Suzuki M; Nagata K; Maruhashi A; Kinash Y; Ono K
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):920-7. PubMed ID: 15465210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neutron capturing irradiation: principle, current results and perspectives].
    Pignol JP; Chauvel P
    Bull Cancer Radiother; 1995; 82(3):283-97. PubMed ID: 8554878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T2 corrected quantification method of L-p-boronophenylalanine using proton magnetic resonance spectroscopy for boron neutron capture therapy.
    Yamamoto Y; Isobe T; Yamamoto T; Shibata Y; Anno I; Nakai K; Shirakawa M; Matsushita A; Sato E; Matsumura A
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S345-7. PubMed ID: 19406648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insight into the mechanisms underlying tumor response to boron neutron capture therapy in the hamster cheek pouch oral cancer model.
    Aromando RF; Heber EM; Trivillin VA; Nigg DW; Schwint AE; Itoiz ME
    J Oral Pathol Med; 2009 May; 38(5):448-54. PubMed ID: 19141057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First evaluation of the biologic effectiveness factors of boron neutron capture therapy (BNCT) in a human colon carcinoma cell line.
    Dagrosa MA; Crivello M; Perona M; Thorp S; Santa Cruz GA; Pozzi E; Casal M; Thomasz L; Cabrini R; Kahl S; Juvenal GJ; Pisarev MA
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):262-8. PubMed ID: 20932650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Boron neutron capture therapy at the crossroads: challenges and opportunities.
    Barth RF
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S3-6. PubMed ID: 19467879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma.
    Coderre JA; Glass JD; Fairchild RG; Micca PL; Fand I; Joel DD
    Cancer Res; 1990 Jan; 50(1):138-41. PubMed ID: 2293547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early effect of boron neutron capture therapy mediated by boronophenylalanine (BPA-BNCT) on mast cells in premalignant tissue and tumors of the hamster cheek pouch.
    Aromando RF; Trivillin VA; Heber EM; Pozzi E; Schwint AE; Itoiz ME
    Oral Oncol; 2010 May; 46(5):355-9. PubMed ID: 20308008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodistribution of GB-10 (Na(2)(10)B10H10 compound for boron neutron capture therapy (BNCT) in an experimental model of oral cancer in the hamster cheek pouch.
    Heber E; Trivillin VA; Nigg D; Kreimann EL; Itoiz ME; Rebagliati RJ; Batistoni D; Schwint AE
    Arch Oral Biol; 2004 Apr; 49(4):313-24. PubMed ID: 15003550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved survival after boron neutron capture therapy of brain tumors by Cereport-mediated blood-brain barrier modulation to enhance delivery of boronophenylalanine.
    Yang W; Barth RF; Bartus RT; Rotaru JH; Moeschberger ML; Ferketich AK; Nawrocky MM; Coderre JA; Goodman JH
    Neurosurgery; 2000 Jul; 47(1):189-97; discussion 197-8. PubMed ID: 10917362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homogeneous boron targeting of heterogeneous tumors for boron neutron capture therapy (BNCT): chemical analyses in the hamster cheek pouch oral cancer model.
    Heber EM; Trivillin VA; Nigg DW; Itoiz ME; Gonzalez BN; Rebagliati RJ; Batistoni D; Kreimann EL; Schwint AE
    Arch Oral Biol; 2006 Oct; 51(10):922-9. PubMed ID: 16696934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
    Henriksson R; Capala J; Michanek A; Lindahl SA; Salford LG; Franzén L; Blomquist E; Westlin JE; Bergenheim AT;
    Radiother Oncol; 2008 Aug; 88(2):183-91. PubMed ID: 18336940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent.
    Matalka KZ; Bailey MQ; Barth RF; Staubus AE; Soloway AH; Moeschberger ML; Coderre JA; Rofstad EK
    Cancer Res; 1993 Jul; 53(14):3308-13. PubMed ID: 8324742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.